Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
British Journal of Cancer|May 14, 1998
Predicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 single-photon emission computerized tomographyY Tokuchi, H Isobe, H Takekawa, et al.
The Japanese Journal of Antibiotics|June 1, 1985
[Clinical evaluation of sisomicin following intravenous drip infusion in respiratory tract infections]F Nagahama, R Ito, Y Sasaki, et al.
Cancer|August 5, 2000
Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lungA Kamimura, M Kamachi, J Nishihira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancerH Okamoto, K Watanabe, Y Nishiwaki, et al.
The Journal of Hospital Infection|July 8, 2008
Bacillus cereus nosocomial infection from reused towels in JapanS Dohmae, T Okubo, W Higuchi, et al.
Clinical Pharmacology and Therapeutics|August 8, 2008
Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecanN Yamamoto, T Takahashi, H Kunikane, et al.
Southern Medical Journal|February 1, 1994
Management of coexistent carotid and coronary artery diseaseD P Halpin, S Riggins, J D Carmichael, et al.
British Journal of Cancer|October 19, 2006
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutationsH Asahina, K Yamazaki, I Kinoshita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2012
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)A Inoue, K Kobayashi, M Maemondo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2015
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902S Sugawara, S Oizumi, K Minato, et al.
Pageof 14